Ziconotide: Can we use it in palliative care?

Eric E. Prommer

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

Ziconotide (PRIALT®) is a new nonopioid treatment for chronic pain. It is apeptide that is the synthetic analog of the omega-conotoxin, derived from the marine snail, Conus magus. The therapeutic benefit ofziconotide derives from its potent and selective blockade of neuronal N-type voltage-sensitive calcium channels. Interference with these channels inhibits input from pain-sensing primary nociceptors. A recent clinical trial demonstrated that ziconotide has a significant analgesic effect compared to placebo in patients considered intolerant or refractory to other treatment such as systemic analgesics, adjunctive therapies, or intrathecal (IT) morphine. Thus, ziconotide is the first of a new class of agents - N-type calcium channel blockers, or NCCBs. Ziconotide may represent another option for patients with refractory pain.

Original languageEnglish (US)
Pages (from-to)369-374
Number of pages6
JournalAmerican Journal of Hospice and Palliative Medicine
Volume22
Issue number5
DOIs
StatePublished - Jan 1 2005

Keywords

  • Analgesic
  • NCCB
  • Omega-conotoxin
  • PRIALT
  • Pain management
  • Palliative care
  • Ziconotide

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Ziconotide: Can we use it in palliative care?'. Together they form a unique fingerprint.

  • Cite this